| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Qian X | |
| Miller MJ | |||
| Samanta A | |||
| Greene MI | |||
| Peterson NC | |||
| Dougall WC | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2109-2123 | |
| P577 | publication date | 1994-08-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies | |
| P478 | volume | 9 |
| Q28594363 | A dual role of erbB2 in myelination and in expansion of the schwann cell precursor pool |
| Q24648517 | A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor |
| Q41086857 | Activation of ErbB2 during wallerian degeneration of sciatic nerve |
| Q33778555 | Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface |
| Q35112126 | Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. |
| Q24297853 | An EGR2/CITED1 transcription factor complex and the 14-3-3sigma tumor suppressor are involved in regulating ErbB2 expression in a transgenic-mouse model of human breast cancer |
| Q33692259 | Antiproliferative and apoptotic activities of ketonucleosides and keto-C-glycosides against non-small-cell lung cancer cells with intrinsic drug resistance. |
| Q37528339 | Chromatin modifications sequentially enhance ErbB2 expression in ErbB2-positive breast cancers |
| Q54679578 | Clinical significance of K-ras and c-erbB-2 mutations in pancreatic adenocarcinoma and chronic pancreatitis. |
| Q35746649 | Controlling tumor-derived and vascular endothelial cell growth: role of the 4Ff2 cell surface antigen |
| Q36732202 | Diagnostic Significance of CA15-3 with Combination of HER-2/neu Values at 85th Percentiles in Breast Cancer |
| Q28609149 | Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions |
| Q28678776 | ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer |
| Q36326248 | ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases |
| Q39675035 | ErbB2 is required for muscle spindle and myoblast cell survival. |
| Q40207716 | Establishment and characterization of new mammary adenocarcinoma cell lines derived from double transgenic mice expressing GFP and neu oncogene. |
| Q34253654 | Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer |
| Q42459989 | Expression of the integrin-linked kinase (ILK) in mouse skin: loss of expression in suprabasal layers of the epidermis and up-regulation by erbB-2. |
| Q24797953 | Gene therapy for carcinoma of the breast: Genetic ablation strategies |
| Q41442987 | Growth factors in bladder cancer |
| Q36648369 | Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment |
| Q39965289 | Heregulin-beta promotes matrix metalloproteinase-7 expression via HER2-mediated AP-1 activation in MCF-7 cells |
| Q40445359 | Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research |
| Q33959349 | Hormonal regulation of type I receptor tyrosine kinase expression in the mammary gland |
| Q24651825 | Induction of the Tat-binding protein 1 gene accompanies the disabling of oncogenic erbB receptor tyrosine kinases |
| Q24551173 | Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain |
| Q33543083 | Molecular chemotherapy for breast cancer |
| Q74670128 | Overexpression of c-erbB-2 protein correlates with chromosomal gain at the c-erbB-2 locus and patient survival in advanced colorectal carcinomas |
| Q53009370 | Relation of oestradiol-mediated growth stimulation with the expression of c-erbB-2 protein in xenotransplanted oestradiol-receptor-positive and -negative breast carcinomas. |
| Q38288271 | Schwann cell tumors express characteristic patterns of CD44 splice variants |
| Q35785948 | Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model |
| Q36748735 | Stress-induced endocytosis and degradation of epidermal growth factor receptor are two independent processes |
| Q37511109 | Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains |
| Q42002200 | SupraMolecular BioVectors (SMBV) improve antisense inhibition of erbB-2 expression |
| Q28118420 | The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor |
| Q24672049 | The estrogen-dependent c-JunER protein causes a reversible loss of mammary epithelial cell polarity involving a destabilization of adherens junctions |
| Q36274097 | Transmembrane domain sequence requirements for activation of the p185c-neu receptor tyrosine kinase |
| Q37332545 | Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors |
| Q36778011 | scFv-based "Grababody" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumors |
| Q37421359 | t10,c12-Conjugated linoleic acid stimulates mammary tumor progression in Her2/ErbB2 mice through activation of both proliferative and survival pathways |
Search more.